Moesin Expression in Clear Cell Renal Cell Carcinoma - Trial NCT06055660
Access comprehensive clinical trial information for NCT06055660 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Completed. The study focuses on Renal Cell Carcinoma. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
Observational
genetic
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Jan 01, 2017
Dec 31, 2021
Primary Outcome
Detection of Moesin in renal cell carcinoma
Summary
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are
 several histological variants of RCC that are associated with variable prognostic outcomes.
 Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire
 some mesenchymal criteria as enhanced invasive potential. There are several cell surface
 molecules that are implicated in EMT. Moesin is one of these molecules that is involved in
 EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting
 Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with
 RCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06055660
Non-Device Trial